Viewing Study NCT00838760


Ignite Creation Date: 2025-12-25 @ 2:13 AM
Ignite Modification Date: 2025-12-26 @ 6:22 PM
Study NCT ID: NCT00838760
Status: COMPLETED
Last Update Posted: 2010-04-28
First Post: 2009-02-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Sponsor: Tibotec Pharmaceuticals, Ireland
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module